5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

Affiliation auteurs!!!! Error affiliation !!!!
Titre5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
Type de publicationJournal Article
Year of Publication2021
AuteursGligorov J., Pivot X., Ataseven B., De Laurentiis M., Llombart A., Jung K.H, Manikhas A., Azim H.A, Alexandrou A., Gupta K., Herraez-Baranda L., Tosti N., Restuccia E.
JournalBREAST
Volume56
PaginationS21-S22
Date PublishedAPR
Type of ArticleMeeting Abstract
ISSN0960-9776